Relapsed/Refractory Large B-cell Lymphoma
Also known as: Relapsed or Refractory Diffuse Large B-cell Lymphoma / Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Relapsed or Refractory Diffuse Large B Cell Lymphoma / Relapsed/Refractory Diffuse Large B-cell Lymphoma / Relapsed/Refractory Diffuse Large B Cell Lymphoma / Relapsed /Refractory Diffuse Large B Cell Lymphoma / Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) / Relapsed/Refractory Large B Cell Lymphoma
Drug | Drug Name | Drug Description |
---|---|---|
DB16371 | Glofitamab | A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB16371 | Glofitamab | B-lymphocyte antigen CD20 | target |
DB16371 | Glofitamab | T-cell surface glycoprotein CD3 | target |